BMJ

1. SAXENA S, Skirrow H, Maini A, Hayhoe B, et al
   Consenting children aged under 18 for vaccination and treatment.
   BMJ. 2022;377:e068889.
   

   >> Share

   
   
2. HITCHINGS MDT, Ranzani OT, Lind ML, Dorion M, et al
   Change in covid-19 risk over time following vaccination with CoronaVac: test negative case-control study.
   BMJ. 2022;377:e070102.
   

   >> Share

   
   
3. MAZZILLI S, Moazen B, Stover H, Plugge E, et al
   Covid-19 vaccine in prison: a not-to-be-missed opportunity to promote access to vaccination in adolescents.
   BMJ. 2022;377:o1439.
   

   >> Share

   
   

   
   Clin Infect Dis

4. MONGE S, Rojas-Benedicto A, Olmedo C, Martin-Merino E, et al
   Effectiveness of a second dose of an mRNA vaccine against SARS-CoV-2 Omicron infection in individuals previously infected by other variants.
   Clin Infect Dis. 2022 Jun 10. pii: 6605647. doi: 10.1093.
   

   >> Share

   
   
5. LIM SY, Park S, Kim JY, Kim S, et al
   Comparison of Waning Neutralizing Antibody Responses Against the Omicron Variant 6 Months After Natural SARS-CoV-2 Infection (With/Without subsequent COVID-19 Vaccination) Versus 2-dose COVID-19 Vaccination.
   Clin Infect Dis. 2022 Jun 10. pii: 6605068. doi: 10.1093.
   

   >> Share

   
   
6. RUHLAND A, Fell A, Holzbauer SM, D'Heilly P, et al
   Exposure Outcomes in Fully Vaccinated Healthcare Personnel with Known SARS-CoV-2 Exposure-Minnesota, January-August 2021.
   Clin Infect Dis. 2022 Jun 10. pii: 6605065. doi: 10.1093.
   

   >> Share

   
   
7. BUSCH MP, Stramer SL, Stone M, Yu EA, et al
   Population-weighted seroprevalence from SARS-CoV-2 infection, vaccination, and hybrid immunity among U.S. blood donations from January-December 2021.
   Clin Infect Dis. 2022 Jun 10. pii: 6605072. doi: 10.1093.
   

   >> Share

   
   
8. LI ZN, Liu F, Jefferson S, Horner L, et al
   Multiplex Detection of Antibody Landscapes to SARS-CoV-2/Influenza/Common Human Coronaviruses Following Vaccination or Infection with SARS-CoV-2 and Influenza.
   Clin Infect Dis. 2022 Jun 10. pii: 6605070. doi: 10.1093.
   

   >> Share

   
   
9. TOP KA, Chen RT, Levy O, Ozonoff A, et al
   Advancing the Science of Vaccine Safety during the COVID-19 Pandemic and Beyond: Launching an International Network of Special Immunization Services.
   Clin Infect Dis. 2022 Jun 9. pii: 6605049. doi: 10.1093.
   

   >> Share

   
   

   
   J Immunol

10. NAGASHIMA K, Dzimianski JV, Han J, Abbadi N, et al
    The Pre-Existing Human Antibody Repertoire to Computationally Optimized Influenza H1 Hemagglutinin Vaccines.
    J Immunol. 2022 Jun 13. pii: jimmunol.2101171. doi: 10.4049/jimmunol.2101171.
    

    >> Share

    
    

    
    J Infect

11. WORSLEY CM, van der Mescht MA, Hoffman D, Meyer PWA, et al
    Decline in antibody responses to SARS-CoV-2 post-vaccination poses a risk to health care workers.
    J Infect. 2022 Jun 12. pii: S0163-4453(22)00360.
    

    >> Share

    
    
12. KANG SW, Kim JY, Park H, Lim SY, et al
    Comparison of outward transmission potential between vaccinated and partially vaccinated or unvaccinated individuals with the SARS-CoV-2 delta variant infection.
    J Infect. 2022 Jun 12. pii: S0163-4453(22)00355.
    

    >> Share

    
    
13. XU QY, Li QL, Jia ZJ, Wu MJ, et al
    Is the fourth COVID-19 vaccine dose urgently needed? Revelation from a prospective cohort study.
    J Infect. 2022 Jun 9. pii: S0163-4453(22)00356.
    

    >> Share

    
    
14. JIMENEZ D, Martinez-Sanz J, Sainz T, Calvo C, et al
    Differences in saliva ACE2 activity among infected and non-infected adult and pediatric population exposed to SARS-CoV-2.
    J Infect. 2022 Apr 28. pii: S0163-4453(22)00248.
    

    >> Share

    
    
15. SALVAGNO GL, Henry BM, Pighi L, De Nitto S, et al
    Serum C reactive protein predicts humoral response after BNT162b2 booster administration.
    J Infect. 2022 Apr 8. pii: S0163-4453(22)00197.
    

    >> Share

    
    

    
    J Infect Dis

16. SIEDNER MJ, Alba C, Fitzmaurice KP, Gilbert RF, et al
    Cost-effectiveness of COVID-19 vaccination in low- and middle-income countries.
    J Infect Dis. 2022 Jun 13. pii: 6606162. doi: 10.1093.
    

    >> Share

    
    

    
    J Virol

17. OLCZAK P, Matsui K, Wong M, Alvarez J, et al
    RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer.
    J Virol. 2022 Jun 15:e0056622. doi: 10.1128/jvi.00566.
    

    >> Share

    
    
18. SUN C, Yuan RY, Xie C, Sun JF, et al
    Induction of Broadly Cross-Reactive Antibody Responses to SARS-CoV-2 Variants by S1 Nanoparticle Vaccines.
    J Virol. 2022 Jun 14:e0038322. doi: 10.1128/jvi.00383.
    

    >> Share

    
    
19. VANDOORN E, Stadejek W, Parys A, Chepkwony S, et al
    Pathobiology of an NS1-Truncated H3N2 Swine Influenza Virus Strain in Pigs.
    J Virol. 2022 May 12:e0051922. doi: 10.1128/jvi.00519.
    

    >> Share

    
    
20. TU JJ, Kumar A, Giorgi EE, Eudailey J, et al
    Vertical HIV-1 Transmission in the Setting of Maternal Broad and Potent Antibody Responses.
    J Virol. 2022 May 10:e0023122. doi: 10.1128/jvi.00231.
    

    >> Share

    
    

    
    JAMA

21. LARKIN HD
    Maternal RSV Vaccine Could Protect Infants, Interim Analysis Suggests.
    JAMA. 2022;327:2182.
    

    >> Share

    
    
22. JONES JM, Opsomer JD, Stone M, Benoit T, et al
    Updated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Estimates Based on Blood Donations, July 2020-December 2021.
    JAMA. 2022 Jun 13. pii: 2793517. doi: 10.1001/jama.2022.9745.
    

    >> Share

    
    
23. LI Y
    Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave.
    JAMA. 2022;327:2147-2148.
    

    >> Share

    
    

    
    Lancet

24. LI G, Cappuccini F, Marchevsky NG, Aley PK, et al
    Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
    Lancet. 2022;399:2212-2225.
    

    >> Share

    
    
25. WONG HL, Hu M, Zhou CK, Lloyd PC, et al
    Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases.
    Lancet. 2022;399:2191-2199.
    

    >> Share

    
    
26. PATEL M, Patel M
    Increasing children's global access to COVID-19 vaccines.
    Lancet. 2022;399:2171-2173.
    

    >> Share

    
    
27. HUSBY A, Kober L
    COVID-19 mRNA vaccination and myocarditis or pericarditis.
    Lancet. 2022;399:2168-2169.
    

    >> Share

    
    

    
    MMWR Morb Mortal Wkly Rep

28. DAVLANTES E
    Notes from the Field: Initial Outbreak Response Activity Following Wild Poliovirus Type 1 Detection - Malawi, February 2022.
    MMWR Morb Mortal Wkly Rep. 2022;71:776-777.
    

    >> Share

    
    

    
    N Engl J Med

29. GOLDBERG Y, Mandel M, Bar-On YM, Bodenheimer O, et al
    Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2.
    N Engl J Med. 2022 May 25. doi: 10.1056/NEJMoa2118946.
    

    >> Share

    
    
30. ALTARAWNEH HN, Chemaitelly H, Ayoub HH, Tang P, et al
    Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections.
    N Engl J Med. 2022 Jun 15. doi: 10.1056/NEJMoa2203965.
    

    >> Share

    
    
31. MATUCHANSKY C
    Protection against SARS-CoV-2 after Vaccination and Previous Infection.
    N Engl J Med. 2022;386.
    

    >> Share

    
    
32. HOPKINS S, Hall V, Klenerman P
    Protection against SARS-CoV-2 after Vaccination and Previous Infection. Reply.
    N Engl J Med. 2022;386.
    

    >> Share

    
    
33. LEUCHTER RK, Jackson NJ, Mafi JN, Sarkisian CA, et al
    Association between Covid-19 Vaccination and Influenza Vaccination Rates.
    N Engl J Med. 2022 Jun 15. doi: 10.1056/NEJMc2204560.
    

    >> Share

    
    

    
    Pediatr Infect Dis J

34. KOENRAADS M, Swarthout TD, Bar-Zeev N, Brown C, et al
    Changing Incidence of Invasive Pneumococcal Disease in Infants Less Than 90 Days of Age Before and After Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Blantyre, Malawi: A 14-Year Hospital Based Surveillance Study.
    Pediatr Infect Dis J. 2022 Jun 13. pii: 00006454-990000000-00099.
    

    >> Share

    
    
35. PLOTKIN S
    Serologic Tests for COVID-19 Infections and Vaccination.
    Pediatr Infect Dis J. 2022 Jun 14. pii: 00006454-990000000-00102.
    

    >> Share

    
    
36. BURNETT E, Parashar UD, Winn A, Curns AT, et al
    Major Changes in Spatiotemporal Trends of US Rotavirus Laboratory Detections After Rotavirus Vaccine Introduction-2009-2021.
    Pediatr Infect Dis J. 2022 Jun 1. pii: 00006454-990000000-00087.
    

    >> Share

    
    
37. BIJKER EM, Bateman EAL, Truck J, Patel S, et al
    Screening for Immunodeficiencies in Children With Invasive Pneumococcal Disease: Six-year Experience From a UK Children's Hospital.
    Pediatr Infect Dis J. 2022;41:575-578.
    

    >> Share

    
    

    
    PLoS Med

38. MARTIN CA, Pan D, Melbourne C, Teece L, et al
    Risk factors associated with SARS-CoV-2 infection in a multiethnic cohort of United Kingdom healthcare workers (UK-REACH): A cross-sectional analysis.
    PLoS Med. 2022;19:e1004015.
    

    >> Share

    
    

    
    PLoS One

39. PAWASKAR M, Fergie J, Harley C, Samant S, et al
    Impact of universal varicella vaccination on the use and cost of antibiotics and antivirals for varicella management in the United States.
    PLoS One. 2022;17:e0269916.
    

    >> Share

    
    
40. KOBASHI Y, Shimazu Y, Kawamura T, Nishikawa Y, et al
    Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine.
    PLoS One. 2022;17:e0269917.
    

    >> Share

    
    
41. RANGELOVA V, Raycheva R, Sariyan S, Kevorkyan A, et al
    Reporting adverse events of COVID-19 vaccines: The case of Bulgaria.
    PLoS One. 2022;17:e0269727.
    

    >> Share

    
    
42. PAPANEOPHYTOU C, Nicolaou A, Pieri M, Nicolaidou V, et al
    Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus.
    PLoS One. 2022;17:e0269885.
    

    >> Share

    
    
43. RANI MDM, Mohamed NA, Solehan HM, Ithnin M, et al
    Assessment of acceptability of the COVID-19 vaccine based on the health belief model among Malaysians-A qualitative approach.
    PLoS One. 2022;17:e0269059.
    

    >> Share

    
    
44. GU M, Taylor B, Pollack HA, Schneider JA, et al
    A pilot study on COVID-19 vaccine hesitancy among healthcare workers in the US.
    PLoS One. 2022;17:e0269320.
    

    >> Share

    
    
45. BOHN-GOLDBAUM E, Owen KB, Lee VYJ, Booy R, et al
    Physical activity and acute exercise benefit influenza vaccination response: A systematic review with individual participant data meta-analysis.
    PLoS One. 2022;17:e0268625.
    

    >> Share

    
    
46. DE ANDRADE PEREIRA SILVA M, Ribeiro HF, Oliveira RR, Pelloso FC, et al
    Factors associated with vaccination against Covid-19 in pregnant and hospitalized postpartum women: A retrospective cohort study.
    PLoS One. 2022;17:e0269091.
    

    >> Share

    
    
47. MA Y, Zhao Y, Chen R, Sun W, et al
    Mucosal immunity of mannose-modified chitosan microspheres loaded with the nontyepable Haemophilus influenzae outer membrane protein P6 in BALB/c mice.
    PLoS One. 2022;17:e0269153.
    

    >> Share

    
    

    
    Vaccine

48. DIAZ-MENENDEZ M, de la Calle-Prieto F, Montejano R, Arsuaga M, et al
    Clinical characteristics and outcome of hospitalized elderly patients with COVID- 19 after vaccine failure.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00751.
    

    >> Share

    
    
49. SHOOTS-REINHARD B, Lawrence ER, Schulkin J, Peters E, et al
    Excluding numeric side-effect information produces lower vaccine intentions.
    Vaccine. 2022 Jun 10. pii: S0264-410X(22)00747.
    

    >> Share

    
    
50. DAYTON L, Miller J, Strickland J, Davey-Rothwell M, et al
    A socio-ecological perspective on parents' intentions to vaccinate their children against COVID-19.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00736.
    

    >> Share

    
    
51. EL-SHESHENY R, El Taweel A, Gomaa MR, Roshdy WH, et al
    Induced humoral immunity of different types of vaccines against most common variants of SARS-CoV-2 in Egypt prior to Omicron outbreak.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00734.
    

    >> Share

    
    
52. SHANMUGARAJ B, Khorattanakulchai N, Panapitakkul C, Malla A, et al
    Preclinical evaluation of a plant-derived SARS-CoV-2 subunit vaccine: Protective efficacy, immunogenicity, safety, and toxicity.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00735.
    

    >> Share

    
    
53. ROLLIER CS, Dold C, Blackwell L, Linder A, et al
    Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisation.
    Vaccine. 2022 Jun 10. pii: S0264-410X(22)00539.
    

    >> Share

    
    
54. ZHAO FJ, Liu LT, Wang Z, Wang NX, et al
    Development and immunogenicity evaluation of porcine deltacoronavirus inactivated vaccine with different adjuvants in mice.
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00721.
    

    >> Share

    
    
55. HASHIMOTO M, Nagata N, Homma T, Maeda H, et al
    Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00718.
    

    >> Share

    
    
56. EUGENIA-TOLEDO-ROMANI M, Verdecia-Sanchez L, Rodriguez-Gonzalez M, Rodriguez-Noda L, et al
    Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00717.
    

    >> Share

    
    
57. HALME J, Syrjanen RK, Baum U, Palmu AA, et al
    Effectiveness of trivalent influenza vaccines against hospitalizations due to laboratory-confirmed influenza a in the elderly: Comparison of test-negative design with register-based designs.
    Vaccine. 2022 Jun 9. pii: S0264-410X(22)00716.
    

    >> Share

    
    
58. SLARVE M, Holznecht N, Reza H, Gilkes A, et al
    Recombinant Aspergillus fumigatus antigens Asp f 3 and Asp f 9 in liposomal vaccine protect mice against invasive pulmonary aspergillosis.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00674.
    

    >> Share

    
    
59. FLYNN JA, Weber T, Cejas PJ, Cox KS, et al
    Characterization of humoral and cell-mediated immunity induced by mRNA vaccines expressing influenza hemagglutinin stem and nucleoprotein in mice and nonhuman primates.
    Vaccine. 2022 Jun 6. pii: S0264-410X(22)00382.
    

    >> Share

    
    
60. SLOTTE P, Karlsson LC, Soveri A
    Attitudes towards mandatory vaccination and sanctions for vaccination refusal.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00697.
    

    >> Share

    
    
61. SMITH WJ, Ahl PL, Wang B, Hamm M, et al
    Analytical technology development to monitor the stability of Polysaccharide-Protein conjugate vaccines.
    Vaccine. 2022 Jun 7. pii: S0264-410X(22)00673.
    

    >> Share

    
    
62. OKUNO H, Satoh H, Morino S, Arai S, et al
    Characteristics and incidence of vaccine adverse events after Bacille Calmette-Guerin vaccination: A national surveillance study in Japan from 2013 to 2017.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00672.
    

    >> Share

    
    
63. CHICHILI GR, Smulders R, Santos V, Cywin B, et al
    Phase 1/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00715.
    

    >> Share

    
    
64. LIGHTOWLER MS, Manangazira P, Nackers F, Van Herp M, et al
    Effectiveness of typhoid conjugate vaccine in Zimbabwe used in response to an outbreak among children and young adults: A matched case control study.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00552.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share